• SPX
  • $5,815.26
  • -0.76 %
  • -$44.59
  • DJI
  • $42,740.42
  • -0.75 %
  • -$324.80
  • N225
  • $39,191.72
  • -1.8 %
  • -$718.83
  • FTSE
  • $8,249.28
  • -0.52 %
  • -$43.38
  • IXIC
  • $18,315.59
  • -1.01 %
  • -$187.10
YS Biopharma Co., Ltd. (YS) Earning

YS Biopharma Co., Ltd. (YS) Earning

NASDAQ Currency in USD Disclaimer

Stock Price
Day's range
$0.9
Day's range
$1.1

YS Biopharma Co., Ltd. Analyst EPS Estimates

Quarter Number of Estimates Low Estimate High Estimate Average Estimate
Q1 2024 1 -$0.08 -$0.08 -$0.08
Q2 2024 1 -$0.09 -$0.09 -$0.09
Q3 2024 1 -$0.08 -$0.08 -$0.08
Q4 2024 1 -$0.06 -$0.06 -$0.06
Q1 2025 1 -$0.02 -$0.02 -$0.02

YS Biopharma Co., Ltd. Earnings Date And Information

YS Biopharma Co., Ltd. last posted its earnings results on Friday, April 19th, 2024. The company reported $-0.12 earnings per share for the quarter, missing analysts' consensus estimates of $-0.08 by $0.04. The company had revenue of 164.98 M for the quarter and had revenue of 687.20 M for the year. YS Biopharma Co., Ltd. has generated $-2 earnings per share over the last year ($-1.56 diluted earnings per share) and currently has a price-to-earnings ratio of -2.21. YS Biopharma Co., Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 20th, 2024 based on prior year's report dates.

YS Biopharma Co., Ltd. Earnings History by Quarter

Date Quarter Consensus Estimate Reported EPS Beat/Miss Revenue Estimate Actual Revenue
01/22/2024 Q3 2024 -$0.72 -$0.84 -0.12 $20.11 M $164.98 M
09/29/2023 Q2 2024 -$1.13 $168.62 M $96.82 M
06/29/2023 Q1 2024 -$0.75 $176.27 M
12/30/2022 Q3 2023 -$0.86 $181.65 M
09/29/2022 Q2 2023 $0.09 $194.06 M
06/29/2022 Q1 2023 -$0.21 $205.48 M
 

YS Biopharma Co., Ltd. Earnings: Frequently Asked Questions

  • When is YS Biopharma Co., Ltd.'s earnings date?

    YS Biopharma Co., Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 20th, 2024 based off last year's report dates.

  • How can I listen to YS Biopharma Co., Ltd.'s earnings conference call?

    The conference call for YS Biopharma Co., Ltd.'s latest earnings report can be listened to online.

  • How can I read YS Biopharma Co., Ltd.'s conference call transcript?

    The conference call transcript for YS Biopharma Co., Ltd.'s latest earnings report can be read online.

  • How much revenue does YS Biopharma Co., Ltd. generate each year?

    YS Biopharma Co., Ltd. (:YS) has a recorded annual revenue of $687.20 M.

  • How much profit does YS Biopharma Co., Ltd. generate each year?

    YS Biopharma Co., Ltd. (:YS) has a recorded net income of $687.20 M. YS Biopharma Co., Ltd. has generated $-1.56 earnings per share over the last four quarters.

  • What is YS Biopharma Co., Ltd.'s price-to-earnings ratio?

    YS Biopharma Co., Ltd. (:YS) has a price-to-earnings ratio of -2.21 and price/earnings-to-growth ratio is 0.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.